Dear Canavan Community,
Aspa Therapeutics, a BridgeBio company, shared additional encouraging data from the CANaspire gene therapy trial during an invited presentation at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The ASGCT holds this scientific conference to showcase the latest research from international experts in gene and cell therapy. Dr. Florian Eichler, principal investigator of the CANaspire clinical trial, presented new findings from the study on Saturday, May 20, 2023. The presentation summarized early results from the first six CANaspire participants who received Aspa’s investigational gene therapy, BBP-812. The main findings presented:
Magnetic Resonance Imaging (MRI): White Matter
Aspa Therapeutics continues to enroll new participants for the CANaspire gene therapy clinical trial. To be considered for screening for potential participation, a child must meet the following criteria:
We at Aspa Therapeutics are grateful for the continued partnership with advocacy organizations and families of the Canavan community as we work together to advance a more meaningful understanding of the natural history of Canavan disease as well as a potential therapeutic option for affected children. A special thanks to all the children and families who have participated and expressed interest in participating in these important studies. Updates about the program can always be found on www.treatcanavan.com, https://clinicaltrials.gov/ct2/show/NCT04998396, or www.aspatx.com. Questions and comments are welcome. Please write to firstname.lastname@example.org.
The Aspa Therapeutics Team